Vantage logo

Pressure on Abbvie's pipeline grows

Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.

Vantage logo

Mustang and the bubble boy bubble

The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.

Vantage logo

Boehringer pushes pipeline progress

The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…

Vantage logo

The bubble bursts for Proteostasis

Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.